Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
100
-
Total 13F shares, excl. options
-
17.5M
-
Shares change
-
+776K
-
Total reported value, excl. options
-
$659M
-
Value change
-
+$33.2M
-
Number of buys
-
55
-
Number of sells
-
-34
-
Price
-
$37.62
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q3 2022
120 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2022.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17.5M shares
of 40.6M outstanding shares and own 43.14% of the company stock.
Largest 10 shareholders include FMR LLC (3.86M shares), ORBIMED ADVISORS LLC (1.68M shares), BlackRock Inc. (1.46M shares), ALKEON CAPITAL MANAGEMENT LLC (1.21M shares), STATE STREET CORP (934K shares), VANGUARD GROUP INC (907K shares), Nantahala Capital Management, LLC (846K shares), First Light Asset Management, LLC (598K shares), CITIGROUP INC (476K shares), and CITADEL ADVISORS LLC (428K shares).
This table shows the top 100 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.